Archer DX

Products

Heme v2


The Archer® FusionPlex Heme v2 panel is an ribonucleic acid (RNA)-based targeted sequencing test that detects and identifies fusions of 87 genes associated with hematological malignancies. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.

Read More »
Lung


The Archer® FusionPlex Lung panel is a targeted next-generation sequencing (NGS) test to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.

Read More »
Comprehensive Thyroid & Lung


The Archer® FusionPlex Comprehensive Thyroid and Lung (CTL) panel is a targeted next-generation sequencing (NGS) panel to detect gene fusions, single-nucleotide variant (SNV), indels, splicing and gene expression in 36 genes associated with lung and thyroid cancers. This panel complements the Archer VariantPlex® CTL panel for comprehensive mutation profiling of fusions, copy number variations (CNVs) and variants.

Read More »
Inherited Disease Tests

Archer® VariantPlex® panels for inherited diseases are highly customizable tests that deliver comprehensive coverage of target exons for genes associated with breast cancer risk (BRCA 1/2 & PALB2) and cystic fibrosis (CFTR).

Read More »
Liquid Biopsy Tests


The Archer® LiquidPlex panel for Illumina® is an advanced and user-friendly solution for targeted next-generation sequencing (NGS) of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly found mutated in solid tumor type cancers.

Read More »
Immune Repertoire Analysis


Archer® Immunoverse™ panels are targeted next-generation sequencing (NGS) tests to characterize the human immune repertoire from RNA input. Powered by Anchored Multiplex PCR (AMP™), the lyophilized reagents uniquely tag and amplify V(D)J rearrangements for clonotype identification and frequency reporting.

Read More »
ALK RET ROS1 v2


The Archer® FusionPlex ALK, RET, ROS1 v2 panel is a targeted sequencing test to simultaneously detect and identify fusions and mutations of human ALK, RET and ROS1 genes. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions of all genes in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. The panel also detects select insertions and point mutations in ALK and RET, including those reported in cell-based tests to convey crizotinib resistance.

Read More »
NTRK Fusion Detection

NTRK fusions are critical events in cancer genomics and are notoriously difficult to detect. Archer® FusionPlex® next-generation sequencing (NGS) tests provide sensitive NTRK fusion detection without prior knowledge of fusion partners.

Read More »
Oncology Research


The Archer® FusionPlex Oncology Research panel is a targeted next-generation sequencing (NGS) test to simultaneously detect and identify fusions and other mutations associated with 74 genes found in ribonucleic acid (RNA) transcripts that are linked to various cancers. This panel is extensive and purpose-built to advance fusion discovery, including research efforts in the area of Ph-like acute lymphoblastic leukemia (ALL) fusions.

Read More »
Sarcoma


The Archer® FusionPlex Sarcoma panel is a targeted sequencing test to simultaneously detect and identify fusions of 26 genes associated with soft tissue cancers. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.

Read More »

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.